The primary objective was to evaluate the short-and long-term toxic effects of radioiodine ( 131 I) therapy on bone marrow function in differentiated thyroid carcinoma (DTC) patients. The secondary objective was to define characteristics of patients at risk for impaired bone marrow function after 131 I treatment.
INTRODUCTION
Differentiated thyroid cancer (DTC) is the most common endocrine malignancy, treated by (near-) total thyroidectomy followed by ablation of remnant tissue with radioiodine ( 131 I) therapy. 1,2 131 I treatment is associated with a significant lower rate of recurrences, metastatic disease, and overall mortality in DTC patients, 3, 4 although the benefits of this treatment are uncertain for patients with low-risk disease. 5 The overall 10-year survival rate of more than 80% 6, 7 has led to an increasing interest in long-term consequences of treatment because 131 I treatment is associated with several adverse effects on the gonads and salivary and lacrimal glands. [8] [9] [10] [11] Furthermore, it is associated with the long-term risk of developing a secondary malignancy, 12 although this remains controversial. 6 Data regarding the toxic effects of 131 I on bone marrow function are scarce. It is known that treatment with 131 I can cause bone marrow suppression and ultimately, although rarely, lead to severe pancytopenia in patients with extensive metastasized disease. [13] [14] [15] A significant decrease of white blood cell and platelet counts 1 year after 131 I ablation with 100 mCi (on average) was described in 206 patients. 16 Another study showed an incidence of 36% for anemia, 10% for leukopenia, and 3% for transient thrombocytopenia in 159 patients during a 10-year follow-up period. 13 Furthermore, a statistically significant decrease of hemoglobin (Hb), hematocrit, and platelets was reported in a total of 50 DTC patients with metastatic disease 1 year after the last 131 I treatment with a cumulative dose of at least 250 mCi. 17 More severe bone marrow toxicity was described in another study; 15 high-grade anemia, leukopenia, and/or thrombocytopenia occurred in 10 of 107 DTC patients with bone metastases after high doses (up to 1700 mCi) of 131 I.
To our knowledge, no studies have been performed focusing longitudinally on both short-and longterm effects of 131 I on all main blood count parameters in a large cohort representative of the general DTC population. Moreover, no previous studies have provided a risk profile of patients at highest risk for hematopoietic toxicity of 131 I. Therefore, the primary aim of this study was to evaluate the short-and long-term toxic effects of 131 I therapy on bone marrow function in DTC patients. Our secondary aim was to define characteristics of patients at risk for impaired bone marrow function after 131 I treatment.
PATIENTS AND METHODS

Patients
All DTC patients treated with 131 I in our tertiary referral center between January 1989 and July 2013 were eligible for inclusion. This inclusion date was chosen because from that time on, the laboratory data were structurally available in (electronic) health records. Patients with missing data at baseline, or at both 3 and 6 months after the last 131 I treatment, were excluded. Treatment with external radiotherapy and cytostatic and/or targeted drugs in history and/or up to 2 years after the last 131 I therapy were also reasons for exclusion. Additional exclusion criteria were (a history of ) malignancy other than DTC (except for basal cell carcinoma), chronic inflammatory disease, medication that could have influenced blood counts at the time of 131 I treatment, and iron substitution for more than 2 months. Patients with a hemorrhage during or after surgery (with an Hb decrease of ≥ 1.5 mmol/L), inflammation, or active infection were excluded as well. If patients received external radiotherapy or experienced morbidity as described above later than 2 years after completion of 131 I therapy, the potentially influenced blood counts were not incorporated for analysis. Furthermore, we evaluated total blood counts. Therefore, we excluded patients that missed at least one of the three parameters (Hb, leukocytes, and/or platelets).
Because bone marrow aspiration and subsequent culturing of colony forming cells were not found to be superior to peripheral blood count testing in predicting impaired bone marrow function, 14 we decided to evaluate effects of 131 I therapy on bone marrow by comparing the absolute blood counts of maximally 6 weeks before the first 131 I treatment (defined as baseline) with those determined at 3 and 6 months and at 1 and 5 years after completion of 131 I therapy. We defined impaired bone marrow function as a (significant) decrease from baseline in peripheral blood counts. Supplemental Figure 1 shows the time schedule for the analysis of the blood counts.
Treatment and follow-up
Patients were treated in accordance with the previously described treatment protocol. 18 Blood count analyses were routinely performed at the outpatient clinic at 3 months after treatment both after ablation and each subsequent treatment. Further follow-up of blood counts was performed on indication and was dependent on the physician and clinical situation of the patient. In short, all patients underwent a (near-) total thyroidectomy and, where indicated, a lymph node dissection, followed by 131 I ablation with fixed dosing regimens of 50 -150 mCi (1850 -5550 MBq). Most patients were prepared with thyroid hormone withdrawal; recombinant human TSH was used in selected cases. Persistent detectable thyroglobulin or the existence of thyroglobulin antibodies were reason for subsequent 131 I treatment 3 -6 months after ablation. As of April 2008, the minimal time lag between the two treatments was extended from 3 to 6 months, based on the revised guidelines. 19 
Data collection
Patient and treatment characteristics, as well as blood count values, were retrospectively derived from the (electronic) health record. Age was defined as age of the patient at first 131 I treatment. For tumor staging, the data of the initial histology reports were used. We restaged the resected tumors of the analyzed patients according to the seventh edition of the tumor node metastasis (TNM) classification. 20 Until 2005 assays of Beckman Coulter were used for estimation of Hb, leukocytes, and platelet counts. Since 2005 the Sysmex XE2100 (Sysmex Corp) has been used. According to Dutch law, ie, Medical Research Involving Human Subjects, no approval was necessary for retrospective data collection. Data sets were fully anonymized during data analysis.
Statistical analysis
Data are expressed as mean±SD or median with interquartile range (IQR), as appropriate. Baseline characteristics were compared between patients included and excluded for analysis, using a χ 2 test and a parametric t test.
For the primary analyses of Hb, we corrected for gender because men and women have different reference values. A paired-samples t test was used to test whether the baseline blood counts differed from values at 3 and 6 months and at 1 and 5 years after completion of 131 I therapy.
Because platelet counts are less influenced by external factors than Hb and leukocytes, we focused solely on platelet counts for the analysis of risk factors, which was our secondary aim. Characteristics of patients with a platelet count below normal value (150 × 10 9 /L) within 1 year after completion of 131 I therapy were compared with patients without thrombocytopenia, provided that patients with post-treatment thrombocytopenia had normal platelet counts at baseline. The χ 2 test was performed to compare the following characteristics of patients with thrombocytopenia: tumor stage (TX-T3 vs T4, NX-N0 vs N1, MX-M0 vs M1), histology (papillary vs follicular including Hürthle cell carcinoma), and gender (male vs female). For the same purpose, we analyzed age using the parametric t test, and cumulative dose using the nonparametric Mann-Whitney U test. We subsequently performed logistic regression analyses to identify variables associated with thrombocytopenia. We first inserted all the variables (age, gender, histology, TNM stage, and cumulative 131 I dose) into a crude model. Thereafter covariates that were significantly associated with thrombocytopenia were inserted into the adjusted model.
All tests performed were two sided, and a value of p < 0.05 was considered statistically significant. IBM SPSS Statistics version 22 was used for all analyses.
RESULTS Patients
A total of 629 DTC patients were eligible. Of these, 123 patients were excluded because of comorbidity and/or treatment and 34 because of missing baseline/follow-up blood counts. Furthermore, of 141 patients, at least one blood count (platelets/Hb/leukocytes) was missing; these patients were also excluded (see flow chart in Figure 1 and Supplemental Table 1 for more detailed exclusion criteria). Finally, 331 DTC patients were included for analysis.
Eleven patients received external radiotherapy or experienced morbidity as described above between 2 and 5 years after completion of 131 I therapy. Potentially influenced blood counts were not incorporated for analysis.
A total of 221 patients received no further 131 I therapy after ablation, whereas 100 patients underwent subsequent therapies. Table 1 shows the baseline characteristics of the 331 included DTC patients. A total of 245 patients (74.0%) were female, and their mean±SD age was 47.5 ± 17.2 years. With 75.2%, most tumors were of the papillary type (n = 249) and 24.8% were follicular (n = 82; of which 4.8% was Hürthle cell carcinoma (n = 16)). When compared with the excluded patients, the included patients were younger (47.5 vs 51.8 years) and had less aggressive disease (24.8% follicular thyroid carcinoma vs 32.2%, 15.4% T4 vs 22.1%, 6.9% M1 vs 12.4%). 
Baseline characteristics
Short-and long-term bone marrow effects
The median administered cumulative 131 I dose was 150 mCi (IQR 50 -300 mCi). Figure 2 shows the course of mean blood counts after 131 I therapy (see Supplemental Table 2 for more details). Platelets were decreased 6 months after the last 131 I treatment (p = 0.022), remained decreased after 1 year (p = 0.002), but were no longer significantly lower 5 years after the last treatment (p = 0.343). Mean±SD platelet values were 260 ± 70.7 × 10 9 /L at baseline, compared with 228 ± 72.3 × 10 9 /L, and 224 ± 71.9 × 10 9 /L after 6 months and 1 year after treatment, respectively. Leukocyte counts were significantly lower compared with baseline after 3 months (p < 0.001), remained decreased at 6 months and 1 year after the last treatment (p < 0.001 and p = 0.006, respectively), but did not differ significantly with baseline values 5 years after the last treatment (p = 0.412; 7.0 ± 2.1 × 10 9 /L at baseline, compared with 6.2 ± 2.0 × 10 9 /L, 5.8 ± 2.1 × 10 9 /L, and 6.6 ± 2.5 × 10 9 /L, after 3 and 6 months and 1 year after treatment, respectively). Hb was significantly higher 3 months after the last treatment as compared with baseline values in both men and women (p = 0.002 and p < 0.001, respectively). In men, Hb increased from 9.2 ± 0.6 mmol/L at baseline to 9.5 ± 0.9 mmol/L 3 months after treatment. In women, this increase was from 8.4 ± 0.7 mmol/L to 8.7 ± 0.8 mmol/L. Hb values from 6 months after the treatment were comparable with baseline. A minor percentage of the analyzed patients had a cytopenia after treatment (Supplemental Table 3 ). However, none of those cytopenias required medical intervention (Supplemental Table 4 ).
Risk factors for impairment of bone marrow function
Fourteen patients (4.2%) developed transient thrombocytopenia within 1 year after completion of 131 I therapy and 317 did not ( Table 2) . Patients with thrombocytopenia were older (p = 0.004), were more often of male gender (p = 0.043), presented with an initially greater tumor size (p = 0.011), and received a higher cumulative 131 I dose (p < 0.001). These variables were significantly associated with developing thrombocytopenia in the crude logistic regression analysis (p = 0.007, p = 0.045, p = 0.007, and p < 0.001, respectively). After multivariate testing, the cumulative radioiodine dose remained significantly associated with thrombocytopenia (p < 0.001), independent of age, gender, and initial tumor size (see Table 3 ). 
DISCUSSION
In this study we showed that after 131 I treatment bone marrow function was not compromised in the long term in a general DTC population. However, we did observe that up to 1 year after the completion of 131 I therapy, there were significant decreases of platelet and leukocyte counts as compared with baseline values. The clinical impact of the cytopenias was negligible because no severe complications were observed in the cohort analyzed. The cumulative 131 I dose was independently associated with posttreatment thrombocytopenia.
Our study is the first to show both short-and long-term effects of 131 I therapy on bone marrow function in a large general DTC cohort. Previous studies were limited by selected, or not clearly defined, populations and only short-term follow-up. Fifty years ago the effects of 131 I therapy were already reported in 159 DTC patients but without clearly defined characteristics like tumor histology and the presence of metastases. Of those patients 36% had transient anemia, 3% thrombocytopenia, and 10% leukopenia after completion of 131 I therapy. 13 Another study described the effects after a single dose 131 I. 16 A significant transient decrease of platelet and leukocyte counts was shown, although the majority (78%; n = 161 patients) of these 206 patients were pretreated with recombinant human TSH. 16 Padovani et al 17 showed a significant decrease of blood counts in a patient group that was overrepresented by patients with distant metastases at presentation (62%), of whom the majority (58%) received external radiotherapy at some point during follow-up. This does not correspond to the incidence of distant metastases in the general population of DTC patients, which historically was approximately 9%, 21 and currently ranges from 3.2% to 6.7% due to an increased diagnosis of low-risk disease. 22, 23 Moreover, patients who received less than 250 mCi were excluded from analysis in that study. 17 Surprisingly, we found a significant increase of Hb in both men and women 3 months after treatment. A possible explanation for this phenomenon could be that the short-term hypothyroid state prior to the 131 I treatment may have caused a relatively anemic state (anemia was present in 24 patients, 7.3%), which in turn recovered after the administration of thyroid hormone treatment after the 131 I therapy. 1, 24 Furthermore, the postsurgical state of patients could have caused a lowered Hb level, which recovered over time. It is thus possible that the baseline values of Hb in men and women were rather low. Relative sparing of red blood cell production after radiation is, however, a well-known phenomenon, 16, 25 which could explain why no significant decreases of Hb were observed in our study.
A strength of our study is that all patients with morbidities that could influence peripheral blood counts, as well as patients treated with external radiotherapy, were excluded from analysis. Our findings can therefore be applied to the general DTC population. Moreover, we describe both the short-and long-term effects on blood counts. To the best of our knowledge, this has not previously been performed using such a large representative DTC cohort.
A limitation of this study is that patients with abnormal blood counts may be overrepresented in our cohort (introducing a selection bias) because blood counts may have been checked more frequently in this group. However, this effect will be minimal because the follow-up intervals for the outpatient clinic controls are fixed in our standard treatment and follow-up protocols. Moreover, if other morbidities had led to extra laboratory controls, the patient would already have been excluded. Another limitation is that progressive disease with extensive bone marrow invasion, and not the 131 I treatment, may have led to impaired hematopoiesis and decreases in peripheral blood counts. 26 This effect was, however, very limited because only a small minority of patients had bone metastases. Furthermore, the retrospective design of this study does not allow us to draw conclusions about causality between blood count changes and 131 I treatment.
Although the prognosis of DTC patients is favorable, it is important to determine the toxic hematological effects of 131 I in these patients. Especially for patients with extensive disease, it is vital to maintain bone marrow reserves of sufficient quality for the next stage of treatment. These patients may benefit from the new and promising targeted approach using tyrosine kinase inhibitors, which may also cause hematological toxicity. 27 For high-risk patients who are expected to receive high cumulative 131 I doses, one can consider offering pre-131 I treatment stem cell preservation or treating the patient using 124 I guided dosimetry, although data concerning potential benefits of those approaches are lacking. 17, 28 In conclusion, our study shows that post-131 I treatment platelets and leukocytes were transiently decreased compared with pretreatment values in a general DTC population. Cumulative 131 I dose was independently associated with thrombocytopenia. Both platelet and leukocyte counts normalized to baseline levels at 5 years after treatment. This implies that in most patients the clinical effects of bone marrow toxicity are limited.
